in: PubMed | Google Scholar 1 Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA
What can patients do to minimise their risk
Comparing weight management approaches after gallbladder removal Managing digestive symptoms Without a gallbladder, your digestive system works differently, which may influence how you experience Wegovy treatment
An increased risk of NAFLD (Non-alcoholic fatty liver disease) is seen in obese patients, with annual burdens in the treatment of NAFLD estimated to be in the hundreds of billions for the US [10]
Surprisingly, GLP-1RAs, such as liraglutide, lixisenatide, and semaglutide, have showed outstandingly neuroprotective effects on animal models of PD (63, 64)
Cell Metab (2017) 25:77796